Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative clinical performance of two types of drug-eluting stents with abluminal biodegradable polymer coating: Five-year results of the DESTINY randomized trial.
Prado GFA Jr, Abizaid AAC, Meireles GC, Sarmento-Leite R, Prudente M, Cantarelli M, Dourado AD, Jr JM, Perin MA, Costantini C, Costa R, Costa JR, Chamie D, Campos CM, Ribeiro EE, Lemos PA. Prado GFA Jr, et al. Among authors: perin ma. Rev Port Cardiol (Engl Ed). 2021 Feb;40(2):71-76. doi: 10.1016/j.repc.2020.05.017. Epub 2021 Jan 2. Rev Port Cardiol (Engl Ed). 2021. PMID: 33402278 Free article. Clinical Trial. English, Portuguese.
Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS Jr, Ribeiro EE. Lemos PA, et al. Among authors: perin ma. EuroIntervention. 2012 May 15;8(1):117-9. doi: 10.4244/EIJV8I1A18. EuroIntervention. 2012. PMID: 22580255 Free article. Clinical Trial.
Metallic Limus-Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra-Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial.
Lemos PA, Abizaid AA, Meireles GC, Sarmento-Leite R, Prudente M, Cantarelli M, Dourado AD, Mariani J Jr, Perin MA, Costantini C, Costa RA, Costa JR, Chamie D, Campos CA, Ribeiro E. Lemos PA, et al. Among authors: perin ma. Cardiovasc Ther. 2015 Dec;33(6):367-71. doi: 10.1111/1755-5922.12159. Cardiovasc Ther. 2015. PMID: 26352896 Free article. Clinical Trial.
One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials.
de Ribamar Costa J Jr, Abizaid A, Bartorelli AL, Whitbourn R, Jepson N, Perin M, Steinwender C, Stuteville M, Ediebah D, Sudhir K, Serruys PW. de Ribamar Costa J Jr, et al. EuroIntervention. 2016 Nov 20;12(10):1255-1262. doi: 10.4244/EIJV12I10A206. EuroIntervention. 2016. PMID: 27866134 Free article. Clinical Trial.
Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS Jr, Ribeiro EE, Martinez EE; PAINT trial investigators. Lemos PA, et al. Among authors: perin ma. Catheter Cardiovasc Interv. 2009 Nov 1;74(5):665-73. doi: 10.1002/ccd.22166. Catheter Cardiovasc Interv. 2009. PMID: 19670303 Clinical Trial.
Rationale and design for the PAINT randomized trial.
Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS Jr, Ribeiro EE, Martinez EE; PAINT study. Lemos PA, et al. Among authors: perin ma. Arq Bras Cardiol. 2009 Dec;93(6):547-53, 590-7. doi: 10.1590/s0066-782x2009001200006. Arq Bras Cardiol. 2009. PMID: 20379631 Free article. Clinical Trial. English, Portuguese.
Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB 3rd, de Paula JE, Mangione JA, Salvadori D Jr, Gusmão MO, Castello H Jr, Nicolela E Jr, Perin MA, Devito FS, Marin-Neto JA, Abizaid A. Feres F, et al. Among authors: perin ma. Am Heart J. 2012 Dec;164(6):810-6.e3. doi: 10.1016/j.ahj.2012.09.009. Epub 2012 Nov 14. Am Heart J. 2012. PMID: 23194480 Clinical Trial.
64 results